Serum CA 15.3 levels in patients with general pathology and malignant diseases (excluding breast cancer).
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to G Encabo.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
In this brief communication, the authors indicate that amounts of neuron-specific enolase higher than 30 ng/ml are observed only in 1% of non-tumoral processes, and that when found in patients with respiratory symptoms a microcytic carcinoma of the lung can be suspected in 97% of the cases.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
In order to know the usefulness of beta-2-microglubulin as a tumor marker, the authors measured by radioimmunoassay its serum concentration in 222 patients with solid tumors of different localization. 116 patients with hematologic neoplasms, and 254 cases grouping healthy individuals and patients with diseases other than cancer. The upper limit of normality was considered as 3 micrograms/ml; 35.6 per 100 of the investigated solid tumors and 43.8 per 100 of the blood-forming organs neoplasms gave values higher than 3 micrograms/ml, against only 5 and 10 per 100 of the healthy and non-cancer patients respectively used as a control. Many cancer patients did not show an augmentation of beta-2-microglobulin. The authors consider that beta-2-microglobulin does not offer enough sensitivity and specificity to be used as a tumor marker.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The authors give the preliminary results about the determination of the tissue polypeptide antigen (TPA) in chronic pancreatitis and pancreas exocrine tumors, indicating that although it can make a differential diagnosis between the two diseases, it is of no practical value because of the frequent increase of TPA in several non tumoral processes that may or may not accompany pancreatic tumors.